AP306 125 mg TID

Phase 2

RR1 Therapeutics

AP306 125 mg TID is one of 22 therapeutic programs targeting Hyperphosphatemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HyperphosphatemiaRecruiting

HyperphosphatemiaPhase 2

Recruiting

Competition

Competitive Landscape

30 competitors in Hyperphosphatemia

#DrugCompanyPhaseTrials

Niacor

AbbVie

Approved

2 2

Fosrenol

Takeda

Approved

1 3

Renvela

Sanofi

Phase 3

5 4

Tums

Otsuka

Phase 3

3 5

Sevelamer Hcl

Novartis

Approved

1 6

Ibsrela

AArdelyx

Phase 3

3 7

Calcium-Based Phosphate Binder

Sanofi

Approved

1 8

Nicotinic Acids

HHeidelberg University

Approved

1 9

Cholestyramine Resin

SSeoul National University Hospital

Approved

1 10

MCI-196

Tanabe Pharma Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Hyperphosphatemia

NCT06712654

Clinical

Trials by Indication[1]

Hyperphosphatemia1 trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance Hemodialysis

Recruiting·AAlebund Pharmaceuticals·Phase 2·NCT06712654·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AP306 125 mg TID. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for AP306 125 mg TID. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — R1 Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: RR1 Therapeutics

AP306 125 mg TID

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Hyperphosphatemia1 trial

References

Drug Info

Quick Facts

Related News